Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®

Summary

This global study (US, Canada, and Australia) will evaluate the safety and effectiveness of the MiniMed 780G system in type 1 adult and pediatric subjects utilizing Fiasp (insulin aspart injection) in a home setting.

Conditions

• Type 1 Diabetes

Interventions

DEVICE

MiniMed 780G System

780G System used with Insulin Fiasp® (Insulin Aspart Injection)

Sponsors & Collaborators

• Medtronic Diabetes

  lead INDUSTRY

Principal Investigators

• David Liljenquist, MD · Rocky Mountain Clinical Research

• Mark Warren, MD · Physicians East

• John Reed, MD · Endocrine Research Solutions

• Frances Broyles, MD · Rainier Clinical Research Center

• Dorothy Shulman, MD · University of South Florida

• Bruce Bode, MD · Atlanta Diabetes Associates

• Halis Akturk, MD · University of Colorado, Denver

• Paul Norwood, MD · Valley Research

• Carla Demeterco-Berggren, MD · Rady's Children's Hospital

• Alexander Abitbol, MD · LMC Clinical Research

• Daniele Pacaud, MD · Alberta Children's Hospital Research Institute

• James Thrasher, MD · Medical Investigations, Inc.

• Bhuvana Sunil, MD · MultiCare Institute for Research & Innovation

• Mark Kipnes, MD · Diabetes and Glandular Disease Clinic, P.A.

• Asheesh Dewan, MD · The Docs LLC

• Barry Reiner, MD · Barry J Reiner MD LLC

• Gnanagurudasan Prakasam, MD · Sutter Institute for Medical Research

• Bruce King, MD · John Hunter Childrens Hospital

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

7 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-03-17

Primary Completion

2024-06-21

Completion

2024-06-21

FDA Device

Yes

Countries

• United States
• Australia
• Canada

Study Locations